"Title","URL","Type","Start year","End year","Countries","Project funding","Funding source(s)","Funding information","Partner(s)","PI institution(s)","Principal investigator","Abstract","Objectives","Methodology","Themes"
"Survey of G6PD variants on Sumba Island and development of PCR primers for each","http://www.malariaeradication.org/mesa-track/survey-g6pd-variants-sumba-island-and-development-pcr-primers-each","Project","Sep 2011","Oct 2012","Indonesia","$53 412","Asia Pacific Malaria Elimination Network (APMEN) ","","Eijkman-Oxford Clinical Research Unit (EOCRU)","Eijkman Institute for Molecular Biology (EIMB), Indonesia","Ari Winasti Satyagraha","","To document the prevalence of G6PD deficiency in Sumba and the presence of any novel G6PD variants.","Epidemiology, Operational research","P. vivax"
"Glucose 6 phosphate enzyme activity dynamics and G6PD qualitative test performance in G6PD deficient Cambodian patients undergoing weekly primaquine for acute uncomplicated Plasmodium vivax","http://www.malariaeradication.org/mesa-track/glucose-6-phosphate-enzyme-activity-dynamics-and-g6pd-qualitative-test-performance-g6pd","Project","Jan 2013","Dec 2014","Cambodia","$51 200","Asia Pacific Malaria Elimination Network (APMEN) ","","National Center for Parasitology, Entomology and Malaria Control, Cambodia (CNM), Eijkman-Oxford Clinical Research Unit (EOCRU), World Health Organization (WHO)","Institut Pasteur du Cambodia (IPC)","Kim Saorin","","To assess the performance of G6PD NAPD spot test over time at presentation with malaria and during the subsequent clinical recovery from vivax malaria.","Operational research","Drug-based strategies, P. vivax"
"CYP2D6 phenotyping in vivax malaria relapsers and non-relapsers in Indonesia","http://www.malariaeradication.org/mesa-track/cyp2d6-phenotyping-vivax-malaria-relapsers-and-non-relapsers-indonesia","Project","","","Indonesia","","Medicines for Malaria Venture (MMV)","","Eijkman-Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology (EIMB), Indonesia, Indonesian Army","University of Indonesia","Rianto Setiabudy","","1. To examine the frequency of fast-intermediate-slow CYP2D6 metabolism of a single dose of dextromethorphan among patients who relapsed after directly observed primaquine therapy compared to those who did not relapse.
2. To compare the CYP2D6 phenotype with CYP2D6 genotype, to compare primaquine pharmacokinetics by phenotype and genotype status
 ","Basic science","P. vivax"
"Radical Cure for Vivax Malaria in Indonesia ","http://www.malariaeradication.org/mesa-track/radical-cure-vivax-malaria-indonesia","Project"," 2012"," 2014","Indonesia","","Medicines for Malaria Venture (MMV)","","Eijkman-Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology (EIMB), Indonesia, Indonesian Army","University of Indonesia","Erni Juwita Nelwan","","To obtain independent, high precision estimates of the efficacy of standard primaquine therapy when combined with artesunate pyronaridine (AS-PYR) or dihydroartemisinin piperaquine (DHA-PP) for radical cure of acute malaria caused by P. vivax. ","Product development & clinical research","Drug-based strategies, P. vivax, Tools for elimination"
"Randomized, Open-Label Trial of Primaquine against Vivax Malaria Relapse in Indonesia","http://www.malariaeradication.org/mesa-track/randomized-open-label-trial-primaquine-against-vivax-malaria-relapse-indonesia","Project"," 2010"," 2012","Indonesia","","Medicines for Malaria Venture (MMV)","","Indonesian Army, Eijkman-Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology (EIMB), Indonesia","University of Indonesia","Inge Sutanto","","1. To measure and compare, using a non-inferior design, the cumulative relapse rate over one year of the two arms relative to the natural relapse rate.
2. To measure the efficacy of the three primaquine combination regimens against relapse, relative to the relapse rate of the artesunate alone regimen.  
 ","Product development & clinical research","P. vivax, Tools for elimination"